Advancing liver gene therapy: Enhanced transduction with GalNAc-bioconjugated rAAV capsids

This study explores a novel strategy to enhance liver-targeted gene delivery, crucial for treating metabolic disorders. While AAV-based gene therapy holds promise, high vector doses raise safety concerns, often requiring the use of corticosteroids and immunosuppression to mitigate immune adverse events. Optimizing capsids to improve hepatocyte transduction efficiency is key to reducing these risks. We employed bioconjugation chemistry to target the Asialoglycoprotein receptor (ASGPR), highly expressed on hepatocytes. Covalent attachment of GalNAc-derived ligands to rAAV2 capsids significantly improved in vivo liver transduction, increasing GFP expression up to threefold. Immunohistochemical co-labeling confirmed exclusive transgene expression in hepatocytes, ensuring specificity. These findings highlight bioconjugation as a promising approach to enhance liver gene therapy while improving safety by lowering vector doses and off-target effects.

Authors

Institutions

Publication Details

Journal
Biomedicine & Pharmacotherapy
Published
2025-06-27
DOI
https://doi.org/10.1016/j.biopha.2025.118300
Primary Topic
Virus-based gene therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Advancing liver gene therapy: Enhanced transduction with GalNAc-bioconjugated rAAV capsids

Mireille Ledevin, Anthony Mellet, Sébastien Depienne, Sébastien G. Gouin et al.
1 links
Biomedicine & Pharmacotherapy
Virus-based gene therapy research
article

Advancing liver gene therapy: Enhanced transduction with GalNAc-bioconjugated rAAV capsids

Mireille Ledevin, Anthony Mellet, Sébastien Depienne, Sébastien G. Gouin, Nicolas Jaulin, Roxane Peumery, Thibaut Larcher, Mohammed Bouzelha, Oumeya Adjali, Zakaria Bouchouireb, Eduard Ayuso, Dimitri Álvarez‐Dorta, Mickaël Guilbaud, Mikaël Croyal, Ludovic Landemarre, Benoît Roubinet, Maia Marchand, David Deniaud, Tiphaine Girard, Caroline Le Guiner, Karine Pavageau, Pierre-Alban Lalys, Mathieu Mével, Audrey Bourdon, Olivia Terceve
article en

Abstract

This study explores a novel strategy to enhance liver-targeted gene delivery, crucial for treating metabolic disorders. While AAV-based gene therapy holds promise, high vector doses raise safety concerns, often requiring the use of corticosteroids and immunosuppression to mitigate immune adverse events. Optimizing capsids to improve hepatocyte transduction efficiency is key to reducing these risks. We employed bioconjugation chemistry to target the Asialoglycoprotein receptor (ASGPR), highly expressed on hepatocytes. Covalent attachment of GalNAc-derived ligands to rAAV2 capsids significantly improved in vivo liver transduction, increasing GFP expression up to threefold. Immunohistochemical co-labeling confirmed exclusive transgene expression in hepatocytes, ensuring specificity. These findings highlight bioconjugation as a promising approach to enhance liver gene therapy while improving safety by lowering vector doses and off-target effects.

Biomedicine & PharmacotherapyVol. 189
Centre National de la Recherche Scientifique (FR), Inserm (FR), Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR), Clinique de l'Acte et PSychosexualité (FR), Chimie et Interdisciplinarité, Synthèse, Analyse, Modélisation (FR), Laboratoire de Cristallographie et Sciences des Matériaux (FR), Institut du Thorax (FR), Oniris (FR), Nantes Université (FR)
Zero hunger
Openalex Percentile: Top 82%
Virus-based gene therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.